摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

tert-butyl 2-{7-[3-(4-cyanophenoxy)propyl]-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl}ethylcarbamate | 335620-86-5

中文名称
——
中文别名
——
英文名称
tert-butyl 2-{7-[3-(4-cyanophenoxy)propyl]-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl}ethylcarbamate
英文别名
(2-{7-[3-(4-Cyanophenoxy)propyl]-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl}ethyl)carbamic acid tert-butyl ester;tert-butyl N-[2-[7-[3-(4-cyanophenoxy)propyl]-9-oxa-3,7-diazabicyclo[3.3.1]nonan-3-yl]ethyl]carbamate
tert-butyl 2-{7-[3-(4-cyanophenoxy)propyl]-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl}ethylcarbamate化学式
CAS
335620-86-5
化学式
C23H34N4O4
mdl
——
分子量
430.547
InChiKey
GXTOJJVRHWFNPK-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.3
  • 重原子数:
    31
  • 可旋转键数:
    10
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.65
  • 拓扑面积:
    87.1
  • 氢给体数:
    1
  • 氢受体数:
    7

反应信息

  • 作为反应物:
    描述:
    tert-butyl 2-{7-[3-(4-cyanophenoxy)propyl]-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl}ethylcarbamate盐酸1,4-二氧六环乙醚 作用下, 以 1,4-二氧六环 为溶剂, 反应 2.0h, 以to give the title compound (3.89 g) as a white solid的产率得到4-{3-[7-(2-Aminoethyl)-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl]-propoxy}benzonitrile, hydrochloride salt
    参考文献:
    名称:
    Novel Oxabispidine Compounds And Their Use In The Treatment Of Cardiac Arrhythmias
    摘要:
    提供了式子(I)的化合物,其中R1、R2、R3、R4、R41至R46、A、B和G的含义如描述中所给,这些化合物在预防和治疗心律失常方面非常有用,尤其是房性和室性心律失常。
    公开号:
    US20090270383A1
  • 作为产物:
    描述:
    4-[3-(9-Oxa-3,7-diazabicyclo[3.3.1]non-3-yl)propoxy]benzonitrile 、 N-Boc-溴乙胺potassium carbonate乙腈 为溶剂, 反应 32.0h, 以to give the sub-title compound (4.5 g) as a yellow solid的产率得到tert-butyl 2-{7-[3-(4-cyanophenoxy)propyl]-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl}ethylcarbamate
    参考文献:
    名称:
    Novel Oxabispidine Compounds And Their Use In The Treatment Of Cardiac Arrhythmias
    摘要:
    提供了式子(I)的化合物,其中R1、R2、R3、R4、R41至R46、A、B和G的含义如描述中所给,这些化合物在预防和治疗心律失常方面非常有用,尤其是房性和室性心律失常。
    公开号:
    US20090270383A1
点击查看最新优质反应信息

文献信息

  • [EN] PHARMACEUTICAL COMBINATION<br/>[FR] COMBINAISON PHARMACEUTIQUE
    申请人:ASTRAZENECA AB
    公开号:WO2003101956A1
    公开(公告)日:2003-12-11
    There is provided a combination product comprising: (1) a compound of claim 1 in WO 02/44145 or a compound of claim 20 in WO 02/44145 (or derivative thereof)or a pharmaceutically-acceptable derivative thereof; and (1) a compound as defined in claim 1 of WO 01/28992 or (2) a compound of Claim 34 of WO 01/28992 or (3) Compound A or B or C or D (or pharmaceutically-acceptable salts thereof) for use in treating arrhythmia or a coagulation controlled complication thereof.
    提供了一种组合产品,包括:(1) WO 02/44145中权利要求1的化合物或WO 02/44145中权利要求20的化合物(或其衍生物)或药用可接受的衍生物;以及(1)WO 01/28992中权利要求1定义的化合物或(2)WO 01/28992中权利要求34的化合物或(3)化合物A或B或C或D(或药用可接受的盐)用于治疗心律不齐或其凝血控制的并发症。
  • [EN] NOVEL OXABISPIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS<br/>[FR] NOUVEAUX COMPOSES OXABISPIDINE ET LEUR UTILISATION DANS LE TRAITEMENT DES ARYTHMIES CARDIAQUES
    申请人:ASTRAZENECA AB
    公开号:WO2005123748A1
    公开(公告)日:2005-12-29
    There is provided compounds of formula (I), wherein R1, R2, R3, R4, R41 to R46, A, B and G have meanings given in the description, which are useful in the prophylaxis and in the treatment of arrhythmias, in particular atrial and ventricular arrhythmias.
    提供了式(I)的化合物,其中R1、R2、R3、R4、R41至R46、A、B和G的含义如描述中所述,这些化合物对预防和治疗心律失常,特别是心房和心室心律失常,具有实用价值。
  • New oxabispidine compounds useful in the treatment of cardiac arrhythmias
    申请人:Bjore Annika
    公开号:US20060166979A1
    公开(公告)日:2006-07-27
    There is provided compounds of formula I, wherein R 1 , R 2 , R 3 , R 4 , R 41 to R 46 , A, B and G have meanings given in the description, which are useful in the prophylaxis and in the treatment of arrhythmias, in particular atrial and ventricular arrhythmias.
    提供了公式I的化合物,其中R1、R2、R3、R4、R41到R46、A、B和G在描述中给出了它们的含义,这些化合物在预防和治疗心律失常方面有用,特别是房性和室性心律失常。
  • Pharmaceutical combination
    申请人:Roth-Rosendahl Ann-Charlotte
    公开号:US20060052314A1
    公开(公告)日:2006-03-09
    There is provided a combination product comprising: (1) a compound of claim 1 in WO 02/44145 or a compound of claim 20 in WO 02/44145 (or derivateive thereof) or a pharmaceutically-acceptable derivative thereof; and (1) a compound as defined in claim 1 or WO 01/28993 or (2) compound of claim 34 or WO 01/28992 or (3) Compound A or B or C or D (or pharmaceutically-acceptable salts therof) for use in treating arrhythmia or a coagulation controlled complicaiton thereof.
    提供了一种组合产品,包括:(1)WO 02/44145中权利要求1的化合物或权利要求20的化合物(或其衍生物)或其药学上可接受的衍生物;和(2)权利要求1或WO 01/28993中定义的化合物或(3)权利要求34或WO 01/28992中的化合物A或B或C或D(或其药学上可接受的盐),用于治疗心律失常或其凝血控制并发症。
  • Novel Oxabispidine Compounds and Their Use in the Treatment of Cardiac Arrhythmias
    申请人:Bjore Annika
    公开号:US20090005558A1
    公开(公告)日:2009-01-01
    There is provided compounds of formula (I), wherein R 1 , R 2 , R 3 , R 4 , R 41 to R 46 , A, B and G have meanings given in the description, which are useful in the prophylaxis and in the treatment of arrhythmias, in particular atrial and ventricular arrhythmias.
    提供了式(I)的化合物,其中R1、R2、R3、R4、R41至R46、A、B和G的含义在说明中给出,这些化合物在预防和治疗心律失常方面是有用的,尤其是房性和室性心律失常。
查看更多